{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-000683","form_type":"8-K","ticker":"MCRB","cik":"0001609809","company_name":"Seres Therapeutics, Inc.","filed_at":"2024-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.802335+00:00","generated_at":"2026-06-07T05:18:22.232987+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Seres Therapeutics amends bylaws to adopt universal proxy rules and update nomination procedures","bullets":["Amended bylaws require compliance with SEC Rule 14a-19 for non-Board director nominee solicitations.","Enhanced disclosure for stockholder nominations includes derivative interests and relationships with the Company.","Stockholders may nominate no more director candidates than open board seats.","Proxies solicited by stockholders must use a proxy card color other than white.","Added personal jurisdiction and service-of-process clarifications for foreign actions under forum selection clause."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-000683","json":"https://secwatch.observer/filing/0001193125-24-000683.json","markdown":"https://secwatch.observer/filing/0001193125-24-000683.md","text":"https://secwatch.observer/filing/0001193125-24-000683.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609809/000119312524000683/0001193125-24-000683-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609809/000119312524000683/d582286d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T05:18:22.232987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"234f8953f3f43b551c09e4e1299bdd4f747e5706","claim":"Seres Therapeutics, Inc.: Adopted Amended and Restated Bylaws with changes to proxy rules, stockholder nominations, and technical updates (effective 2024-01-02).","evidence_excerpt":"On January 2, 2024, the Board of Directors (the “ Board ”) of Seres Therapeutics, Inc., a Delaware corporation (the “ Company ”) approved and adopted the Company’s Amended and Restated Bylaws (the “ Amended and Restated Bylaws ”), which became effective the same day.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312524000683/0001193125-24-000683-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2024-01-02"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}